Top Page
Cellectis SA
(NASDAQ:CLLS)
Cellectis SA (CLLS) vs. SPDR S&P 500 ETF (SPY)
Cellectis SA Business Overview & Revenue Model
Cellectis SA Earnings Call Summary
Cellectis SA Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 75.27M | 41.51M | 755.00K | 19.17M | 30.35M | 51.06M |
| Gross Profit | 65.96M | 32.32M | -6.66M | 10.69M | 28.50M | 49.11M |
| EBITDA | -6.07M | -9.46M | -92.64M | -76.38M | -78.42M | -43.34M |
| Net Income | -35.35M | -36.76M | -101.06M | -106.14M | -114.20M | -81.07M |
Balance Sheet | ||||||
| Total Assets | 343.05M | 383.54M | 334.27M | 261.22M | 382.08M | 469.47M |
| Cash, Cash Equivalents and Short-Term Investments | 52.24M | 260.31M | 203.81M | 97.70M | 186.13M | 268.24M |
| Total Debt | 37.58M | 91.46M | 85.06M | 75.77M | 100.87M | 106.68M |
| Total Liabilities | 242.57M | 252.51M | 249.57M | 135.28M | 145.60M | 160.63M |
| Stockholders Equity | 100.48M | 131.03M | 84.69M | 117.97M | 221.29M | 283.80M |
Cash Flow | ||||||
| Free Cash Flow | -32.71M | 19.52M | -25.82M | -89.89M | -123.12M | -124.68M |
| Operating Cash Flow | -29.09M | 22.10M | -24.75M | -87.44M | -104.56M | -80.26M |
| Investing Cash Flow | -68.60M | -102.63M | -15.51M | -2.76M | 7.28M | -54.34M |
| Financing Cash Flow | -9.70M | 89.80M | 82.86M | 1.15M | 47.52M | 27.32M |
Cellectis SA Technical Analysis
Cellectis SA Risk Analysis
Cellectis SA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $362.52M | ― | -31.07% | ― | 158.54% | 66.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $199.55M | -2.85 | ― | ― | -3.91% | 37.89% | |
46 Neutral | $204.13M | ― | ― | ― | ― | ― | |
43 Neutral | $224.31M | -4.55 | -47.85% | ― | ― | -19.69% | |
36 Underperform | $204.80M | ― | -96.44% | ― | ― | 46.68% | |
33 Underperform | $226.34M | ― | ― | ― | ― | -1072.48% |
Cellectis SA Corporate Events
On December 8, 2025, Cellectis announced promising results from its Phase 1 NATHALI-01 clinical trial for eti-cel, an allogeneic dual CAR-T therapy targeting CD20 and CD22, at the American Society of Hematology meeting. The trial showed an 88% overall response rate and a 63% complete response rate in patients with relapsed/refractory non-Hodgkin lymphoma. The company plans to enhance these results by incorporating low dose Interleukin-2 (IL-2) support, with patient enrollment for this cohort starting in Q1 2026. These developments underscore Cellectis’ innovative approach to improving outcomes for difficult-to-treat cancer patients.
On December 5, 2025, Cellectis S.A. announced a re-filing of Exhibit 4.1.3 related to its Exclusive Patent License Agreement with the University of Minnesota. This amendment allows the company to omit confidential information from material contracts without submitting a confidential treatment request. The changes include adjustments to payment structures and field of use definitions, emphasizing non-agricultural applications. These amendments are expected to streamline Cellectis’s operations by reducing administrative burdens and potentially enhancing its competitive positioning in the biotechnology sector.
On November 19, 2025, Cellectis published an article in Nature Communications highlighting a breakthrough in non-viral gene editing. The company introduced circular single-stranded DNA (CssDNA) as an efficient non-viral DNA donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs). This innovation significantly enhances the potential of non-viral gene therapy by achieving higher knock-in efficiency and applicability to multiple cell types, marking a pivotal advance in the development of next-generation cell and gene therapies.
Cellectis S.A. released its unaudited interim financial report for the nine-month period ending September 30, 2025. The report, prepared in accordance with International Accounting Standard 34, highlights the company’s financial position and operational results. The document also includes management’s discussion and analysis of financial conditions and results of operations, providing insights into the company’s strategic direction and market positioning. This release is significant for stakeholders as it offers a comprehensive view of Cellectis’s financial health and potential challenges, such as regulatory developments and market competition, which could impact its future operations.
Cellectis announced the acceptance of two abstracts for presentation at the ASH 2025 annual meeting, highlighting significant advancements in their clinical trials. The first abstract presents promising preliminary data for eti-cel (UCART20x22) in treating relapsed/refractory non-Hodgkin lymphoma, showing an 86% overall response rate and a 57% complete response rate. The second abstract discusses the correlation between alemtuzumab exposure and response in patients treated with lasme-cel (UCART22) for acute lymphoblastic leukemia, indicating improved responses without increased toxicities. These developments underscore Cellectis’ potential to enhance treatment outcomes for challenging cancer cases.
On October 31, 2025, Cellectis announced that it will release its third-quarter financial results for 2025 on November 7, 2025, after the US market closes. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance during the quarter. Notably, Cellectis will not host a conference call to discuss these results, but its investor relations team is available for inquiries.
On October 16, 2025, Cellectis S.A. hosted an Investors R&D Day, unveiling promising data from the Phase 1 BALLI-01 study of lasme-cel (UCART22) for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study showed lasme-cel was generally well-tolerated and demonstrated significant efficacy, with a 68% overall response rate and 83% achieving minimal residual disease-negative status in the target Phase 2 population. The company announced the initiation of the pivotal Phase 2 trial and outlined a registration path for lasme-cel as a bridge to transplant in r/r ALL, with a Biologics License Application submission anticipated in 2028. This development positions lasme-cel as a potential game-changer in the industry, offering a new treatment option for heavily pretreated patients and potentially capturing a significant share of the market.
On October 16, 2025, Cellectis hosted an R&D Day in New York City, where the company presented the full Phase 1 dataset and outlined the pivotal Phase 2 trial design for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This event highlighted the commercial opportunities and strategic advancements in their pipeline, reinforcing Cellectis’ position in the biotechnology industry as a leader in gene-editing therapies. The presentation of the Phase 1 data and the strategy for Phase 2 trials are significant for stakeholders, as they indicate potential market opportunities and the company’s progress in developing effective treatments for cancer.
Cellectis announced the presentation of new research findings at the ESGCT Annual Congress in Sevilla, Spain, from October 7-10, 2025. The company highlighted the potential of circular single-stranded DNA (CssDNA) as a non-viral template for gene therapy, demonstrating high gene insertion frequency and better engraftment in HSPCs compared to viral methods. Additionally, Cellectis presented a study on TALE base editors, showing no significant off-target effects, supporting their safe use in therapeutic applications. These advancements could enhance Cellectis’ position in the gene therapy industry and offer new opportunities for stakeholders.